Public Sector Pension Investment Board lowered its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 369,352 shares of the biopharmaceutical company’s stock after selling 5,400 shares during the period. Public Sector Pension Investment Board’s holdings in Bristol-Myers Squibb were worth $21,585,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of BMY. Triangle Securities Wealth Management increased its stake in shares of Bristol-Myers Squibb by 79.5% in the third quarter. Triangle Securities Wealth Management now owns 23,854 shares of the biopharmaceutical company’s stock valued at $1,286,000 after buying an additional 10,565 shares during the last quarter. Catawba Capital Management VA increased its stake in shares of Bristol-Myers Squibb by 5.4% in the third quarter. Catawba Capital Management VA now owns 54,206 shares of the biopharmaceutical company’s stock valued at $2,923,000 after buying an additional 2,760 shares during the last quarter. Advisory Services Network LLC increased its stake in shares of Bristol-Myers Squibb by 26.1% in the third quarter. Advisory Services Network LLC now owns 20,845 shares of the biopharmaceutical company’s stock valued at $1,124,000 after buying an additional 4,317 shares during the last quarter. Capital Asset Advisory Services LLC increased its stake in shares of Bristol-Myers Squibb by 6.1% in the third quarter. Capital Asset Advisory Services LLC now owns 5,363 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 310 shares during the last quarter. Finally, Founders Capital Management LLC increased its stake in shares of Bristol-Myers Squibb by 0.4% in the third quarter. Founders Capital Management LLC now owns 4,040 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 18 shares during the last quarter. Hedge funds and other institutional investors own 69.67% of the company’s stock.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) traded up 0.07% on Friday, hitting $53.48. The stock had a trading volume of 5,224,373 shares. Bristol-Myers Squibb Co has a 12-month low of $46.01 and a 12-month high of $77.12. The stock has a 50 day moving average of $55.23 and a 200 day moving average of $54.61. The firm has a market cap of $89.46 billion, a price-to-earnings ratio of 20.18 and a beta of 1.00. Bristol-Myers Squibb also was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 3,241 call options on the stock. This is an increase of 437% compared to the typical volume of 603 call options.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, May 1st. Stockholders of record on Friday, April 7th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Wednesday, April 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.92%. Bristol-Myers Squibb’s dividend payout ratio is presently 58.87%.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/04/22/bristol-myers-squibb-co-bmy-position-decreased-by-public-sector-pension-investment-board.html.
Several research firms have recently issued reports on BMY. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, January 9th. Evercore ISI reissued a “hold” rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Sunday, January 8th. Jefferies Group LLC reissued a “buy” rating and set a $69.00 target price on shares of Bristol-Myers Squibb in a research note on Thursday, January 5th. Vetr cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $56.28 target price on the stock. in a research note on Monday, March 13th. Finally, Piper Jaffray Companies reaffirmed a “neutral” rating and issued a $60.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, March 8th. Twelve investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Buy” and an average price target of $62.48.
In related news, insider Louis S. Schmukler sold 5,000 shares of Bristol-Myers Squibb stock in a transaction on Friday, March 17th. The shares were sold at an average price of $56.49, for a total transaction of $282,450.00. Following the transaction, the insider now owns 21,483 shares in the company, valued at approximately $1,213,574.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Joseph C. Caldarella sold 8,096 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $57.29, for a total transaction of $463,819.84. Following the transaction, the senior vice president now owns 55,637 shares in the company, valued at approximately $3,187,443.73. The disclosure for this sale can be found here. Insiders have sold a total of 190,501 shares of company stock valued at $10,690,203 over the last three months. Corporate insiders own 0.24% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
